BofA upgrades Agilent stock rating to Buy on solid results

BofA Securities upgraded Agilent Technologies to Buy from Neutral and set a $145 price target, citing strong Q2 2026 results that beat expectations across key metrics. Agilent posted core growth of 6.3%, operating margin 80 bps above guidance, EPS of $1.49 versus $1.41 expected, and revenue of $1.83B versus $1.8B consensus. The stock trades near its 52-week low at $115.84, which supports the valuation case but limits immediate market-wide impact.

Analysis

This is less a one-quarter beat story than evidence that Agilent’s replacement-cycle revenue is becoming self-sustaining, which matters because instrument businesses usually inflect slowly and then rerate fast once investors believe the cycle is durable. The market is still pricing A like a mid-single-digit grower with modest multiple expansion potential; if the company can keep converting install-base refreshes into recurring consumables/service pull-through, the earnings power is likely understated over the next 4-6 quarters.

The second-order read-through is to the tools group: names tied to life-science and analytical instrumentation should benefit disproportionately versus broader industrial peers because this is a capex cycle with better visibility and higher gross-margin mix. Suppliers to pharma QA/QC, environmental testing, and applied markets could see a similar pattern of delayed but persistent demand, while weaker chemical-end demand looks more like a mix headwind than a true demand collapse.

The main risk is that the current upgrade may be backward-looking if the beat was driven by timing rather than true acceleration. If macro softness pushes customers to defer upgrades, the next 1-2 quarters can look fine while backlog conversion de-risks, then growth can step down abruptly; that would compress the multiple back toward low-20s P/E quickly. The contrarian angle is that consensus may be underestimating how long replacement cycles can run when installed base aging, regulatory testing demand, and service attach all line up at once — this could be a multi-year rather than merely cyclical rerating.

Key Decisions for Investors

• Go long A on weakness into the next 1-2 sessions; target a re-rating toward the low/mid-130s over 3-6 months if management commentary confirms replacement-cycle durability. Risk/reward is attractive because downside is likely anchored by recent lows, while multiple expansion can add 10-15% without heroic revenue assumptions.
• Pair trade: long A / short a slower-growth tools peer with more cyclical capex exposure over the next quarter. The thesis is that Agilent’s mix is shifting toward higher-quality recurring demand, so relative performance should improve even if the sector stays range-bound.
• Buy 3-6 month call spreads in A rather than stock if you want defined risk ahead of the next earnings cycle. The setup favors upside capture from estimate revisions, but the stock can still gap down if management tones down the durability of the current replacement cycle.
• If A fails to hold above the recent range after the next print, fade the move and look for a retracement trade back toward the 52-week low area. That would indicate the market is treating the beat as a one-off, which would remove the rerating thesis quickly.
• Add a watchlist long on adjacent life-science tools names with similar installed-base economics; if Agilent can sustain this cadence, the spillover to the group could be a cleaner trade than trying to pick the single best performer.